Enoxaparin Dosing in eGFR <15 mL/min
For patients with eGFR <15 mL/min (severe renal impairment), enoxaparin should be dosed at 30 mg subcutaneously once daily for VTE prophylaxis and 1 mg/kg subcutaneously once every 24 hours for therapeutic anticoagulation. This represents a critical dose reduction from standard regimens due to the 2- to 3-fold increased bleeding risk when standard doses are used in severe renal dysfunction 1.
Prophylactic Dosing (VTE Prevention)
- Standard dose: 30 mg subcutaneously once daily
- This applies to hospitalized medical patients, surgical patients (postoperatively), and outpatients requiring prophylaxis
- The manufacturer-recommended dose reduction from 40 mg daily to 30 mg daily is mandatory at creatinine clearance <30 mL/min 1
Therapeutic Dosing (VTE Treatment)
- Standard dose: 1 mg/kg subcutaneously once every 24 hours (instead of the usual twice-daily dosing)
- This represents a 50% reduction in daily dose frequency from the standard 1 mg/kg every 12 hours regimen
- Multiple guidelines consistently support this dosing adjustment 2, 3
Critical Considerations for eGFR <15
Monitoring Strategy
The 2018 ASH guidelines suggest against routine anti-Xa monitoring to guide dose adjustments in renal dysfunction 4. However, this recommendation applies primarily to creatinine clearance 15-30 mL/min. For eGFR <15 mL/min:
- Consider switching to unfractionated heparin (UFH) as the preferred alternative, as it does not rely on renal clearance
- If enoxaparin must be continued, anti-Xa monitoring may be warranted despite guideline recommendations, given the extreme renal impairment
- Target anti-Xa levels: 0.2-0.5 IU/mL for prophylaxis, 0.5-1.5 IU/mL for therapeutic dosing (measured 4-6 hours post-dose after 3-4 doses) 1
Pharmacokinetic Evidence
Enoxaparin clearance is reduced by 44% in severe renal impairment (<30 mL/min), with 71% of the drug excreted unchanged renally 5, 6. The elimination half-life progressively increases with worsening renal function, creating significant accumulation risk with standard dosing 6.
Common Pitfalls to Avoid
Using eGFR instead of creatinine clearance: The Cockcroft-Gault equation (creatinine clearance) should be used for dosing decisions, not eGFR, as eGFR may overestimate renal function in patients with low body surface area 7. Use ideal body weight in the Cockcroft-Gault calculation.
Continuing twice-daily dosing: The most critical error is failing to reduce from every 12 hours to every 24 hours for therapeutic dosing in severe renal impairment—this doubles drug exposure and bleeding risk 1.
Ignoring alternative anticoagulants: At eGFR <15 mL/min, strongly consider UFH or fondaparinux alternatives. Note that fondaparinux is contraindicated at creatinine clearance <30 mL/min 8, 2.
Age considerations: Patients ≥80 years may require even lower doses to achieve target anti-Xa levels, independent of renal function 9. Consider starting at the lower end of dosing ranges in elderly patients with eGFR <15.
Acute Coronary Syndrome Context
For ACS patients specifically, the 2025 ACC/AHA guidelines recommend 1 mg/kg subcutaneously every 24 hours (not every 12 hours) when creatinine clearance is <30 mL/min 8. This applies to both initial therapy and fibrinolytic support scenarios.
When to Avoid Enoxaparin Entirely
Strongly consider switching to UFH in patients with:
- eGFR <15 mL/min (especially if <10 mL/min or on dialysis)
- Age ≥70 years combined with severe renal impairment (based on tinzaparin mortality data, though this may apply to all LMWHs) 1
- Any bleeding complications on reduced-dose enoxaparin
UFH offers the advantage of no renal clearance, immediate reversibility with protamine, and aPTT-guided dosing that accounts for individual pharmacokinetics 8, 2.